Laboratorios Rovi : Q1 earnings in line, outlook maintained
>Overall sales momentum deteriorates materially on very weak CMO, as expected - Total revenues decreased -25% y-o-y in Q1 2024 reaching € 151m, broadly aligned with our estimates and the consensus (-1% and -1% respectively) and posting a 22pp sequential deterioration (vs -3% in Q4, +10% in Q3 and +2% in Q2) due to a tough comp on CMO. In the LMWH franchise, Becat posted a material sequential deterioration after a strong Q4 (-1% vs +18% in Q422) while Hibor also poste...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.